12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OMS ElectroChemotherapy: Interim Phase III data

Delayed interim data from 189 evaluable patients with SCCHN in the open-label, international Phase III HNBE-01 and HNBE-02 trials showed that OMS ElectroChemotherapy met the primary endpoint of preserving quality of life as measured by PSSHN scores vs. surgery. Specifically, PSSHN scores in patients receiving OMS ElectroChemotherapy were reduced to 249 points at 8 months from 257 points at baseline (p=0.59) vs. a significant reduction to 248 points from 269 points for patients receiving surgery (p=0.036). There were no significant differences between...

Read the full 386 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >